Frontlight ResearchEarly access
CompletedNo phase
Compare the Safety and Effectiveness of Two Different Kinds of Stent System in Intracranial Aneurysms
Key facts
- Who runs it
- Sinomed Neurovita Technology Inc.
- Where
- China14 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 203 people enrolled
- Started
- 17 Jan 2024
- Ended
- 20 Nov 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- SINOMED IAS Stent System
- Neuroform Atlas Stent System
- Record updated
- 13 July 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age 18 years to 80 years
- Wide-necked (Wide-necked is defined as width ≥ 4 mm or a dome-to-neck ratio < 2), saccular, intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.5 mm and ≤ 5mm
- Modified Rankin Scale (mRS) ≤ 2
- Subject understands the nature of the procedure, provides voluntary written informed consent prior to the treatment, and is willing to comply with specified follow-up evaluation
- The investigators judged the use of stent-assisted coil embolization to be appropriate for the treatment of intracranial aneurysm
Who cannot take part
- Target aneurysm that has been previously treated with vascular embolization or surgery
- Hospitalized surgical treatment within 30 days before operation, or planned hospitalized surgical treatment within 6 months after surgery
- Currently enrolled in another investigational device or drug study
- Target aneurysms are fusiform aneurysms, dissecting aneurysms, pseudoaneurysms, blood blister-like aneurysms, infected aneurysms, aneurysms associated with arteriovenous malformations
- Subject who had Moyamoya disease, arteriovenous malformations, arteriovenous fistulae, intracranial tumors, or intracranial mass lated to target aneurysms
- Known hypersensitivity/allergies or contraindication to contrast media, stent components, antiplatelets, anticoagulants
- Platelet count <50*103/mm3 (50*109/L) or any known coagulation deficiency, or International normalized ratio (INR)>3.0
- Target aneurysm is an aneurysm requiring staged procedure
- Acutely ruptured aneurysm within 14 days of enrollment
- Hunt and Hess (H\&H) scale ≥3
- Severe stenosis or tortuosity of intracranial arteries or anatomical anomalies that make it difficult to reach the site of the lesion with device
- Life expectancy < 1 year, and unable to complete the required follow-ups
- Female who was pregnant or breastfeeding, women/men planning to havve children in the next year
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of this trial is to evaluate the safety and efficacy of SINOMED IAS in patients with intracranial aneurysms.
The 2 groups in the trial
- SINOMED IAS Stent SystemTreatment being tested
The SINOMED IAS Stent System is intended for use with occlusive devices in the treatment of intracranial aneurysms.
- Neuroform Atlas Stent SystemExisting treatment, for comparison
The Neuroform Atlas Stent System is intended for use with occlusive devices in the treatment of intracranial aneurysms.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Effectiveness of the SINOMED IAS for the Treatment of Intracranial Aneurysms
- Record updated
- 13 July 2026